4th Oct 2019 7:00 am |
RNS |
Fasenra approved in the US for self-administration |
3rd Oct 2019 4:00 pm |
RNS |
Director Declaration |
1st Oct 2019 3:00 pm |
RNS |
Total Voting Rights |
1st Oct 2019 7:05 am |
RNS |
AstraZeneca divests rights for Losec to Cheplaphar |
1st Oct 2019 7:00 am |
RNS |
Update on US regulatory review of PT010 in COPD |
30th Sep 2019 3:30 pm |
RNS |
Lynparza more than doubled the time without |
30th Sep 2019 7:00 am |
RNS |
Tagrisso is the only 1st-line treatment for EGFR- |
30th Sep 2019 7:00 am |
RNS |
Lynparza improved the time women lived without |
23rd Sep 2019 7:00 am |
RNS |
Qtrilmet recommended for approval in EU by CHMP |
18th Sep 2019 7:00 am |
RNS |
AstraZeneca amends collaboration with Ironwood |
9th Sep 2019 8:38 am |
RNS |
Imfinzi is first immunotherapy to show both |
4th Sep 2019 7:11 am |
RNS |
Tagrisso approved in China as a 1st-line treatment |
2nd Sep 2019 3:00 pm |
RNS |
Total Voting Rights |
2nd Sep 2019 7:05 am |
RNS |
Brilinta reduced the risk of cardiovascular events |
2nd Sep 2019 7:00 am |
RNS |
Detailed results from Phase III DAPA-HF trial |
29th Aug 2019 7:00 am |
RNS |
Anifrolumab Phase III trial meets primary endpoint |
28th Aug 2019 7:05 am |
RNS |
Fasenra granted US Orphan Drug Designation for |
28th Aug 2019 7:00 am |
RNS |
Breztri Aerosphere Phase III ETHOS trial met |
22nd Aug 2019 7:00 am |
RNS |
Roxadustat approved in China for the treatment of |
22nd Aug 2019 7:00 am |
RNS |
AstraZeneca agrees to buy US FDA Priority Review |
21st Aug 2019 7:00 am |
RNS |
Update on the Phase III NEPTUNE trial |
20th Aug 2019 7:00 am |
RNS |
Farxiga met primary endpoint in landmark Phase III |
19th Aug 2019 7:00 am |
RNS |
Directorate Change |
14th Aug 2019 7:00 am |
RNS |
Lynparza Phase III PAOLA-1 trial met primary endpo |
14th Aug 2019 7:00 am |
RNS |
Calquence granted US Breakthrough Therapy Designat |
9th Aug 2019 9:28 am |
RNS |
Amendment: Tagrisso significantly improves overall |
9th Aug 2019 7:00 am |
RNS |
Tagrisso significantly improves overall survival |
7th Aug 2019 7:00 am |
RNS |
Lynparza Phase III PROfound trial in HRR* |
5th Aug 2019 7:00 am |
RNS |
Forxiga label updated in the EU in type-2 diabetes |
1st Aug 2019 3:00 pm |
RNS |
Total Voting Rights |
25th Jul 2019 7:00 am |
RNS |
AZN: H1 2019 Results |
15th Jul 2019 7:00 am |
RNS |
Update on US regulatory decision for Farxiga |
12th Jul 2019 7:00 am |
RNS |
Imfinzi granted US Orphan Drug Designation for |
1st Jul 2019 3:00 pm |
RNS |
Total Voting Rights |
1st Jul 2019 7:00 am |
RNS |
Forxiga receives positive EU CHMP opinion for |
1st Jul 2019 7:00 am |
RNS |
Fasenra receives positive EU CHMP opinion for self |
27th Jun 2019 7:00 am |
RNS |
Imfinzi improves overall survival at interim |
19th Jun 2019 7:00 am |
RNS |
Breztri Aerosphere (PT010) approved in Japan for |
19th Jun 2019 7:00 am |
RNS |
Lynparza approved in Japan for 1st-line |
19th Jun 2019 7:00 am |
RNS |
Bevespi Aerosphere approved by the Japanese |